AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2019
Nov 18, 2019
33422_dirs_2019-11-18_1cc2cd67-c982-4910-b01d-2df06365e64c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-11-15
Reporting Person: FREEMAN KEVIN D (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-11-15 | Common Stock | P | 3000 | $3.3586 | Acquired | 14000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 23469 | Direct |
| Common Stock | 16000 | Indirect |
Footnotes
F1: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21